^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Bladder Cancer
    Drug:Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Adv Sci (Weinh)
    Title:

    A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

    Published date:
    10/12/2023
    Excerpt:
    Our data showed that cells with high HER2 expression (5637, T24, and SK-BR-3) were more sensitive to RC48-ADC than low HER2 expression cells (UM-UC-3 and MDA-MB-231).
    DOI:
    https://doi.org/10.1002/advs.202302377